Hyperliquid Strategies Inc

# Hyperliquid Strategies Inc

Listed on Nasdaq under the ticker PURR, Hyperliquid Strategies Inc operates through a biotechnology subsidiary focused on biologic medicines development. The company owns and operates a platform for producing biologic medicines with single or bifunctional mechanisms of action. The company was incorporated in Delaware in 2025 and maintains its headquarters in New York, New York.

The company's primary business centers on its biologic medicines platform, which enables the development of therapeutic agents with defined functional properties. The platform architecture supports both single-action and bifunctional therapeutic approaches, allowing flexibility in drug candidate design and development.

Limited public information is currently available regarding the company's revenue streams, employee headcount, or detailed geographic operational scope beyond its New York headquarters location.